Berran Yucesoy1, Grace E Kissling, Victor J Johnson, Zana L Lummus, Denyse Gautrin, André Cartier, Louis-Philippe Boulet, Joaquin Sastre, Santiago Quirce, Susan M Tarlo, Maria-Jesus Cruz, Xavier Munoz, Michael I Luster, David I Bernstein. 1. Division of Immunology, Allergy and Rheumatology (Drs Yucesoy, Lummus, and Bernstein), University of Cincinnati, Ohio; NIEHS/NIH (Dr Kissling), Research Triangle Park; BRT-Burleson Research Technologies (Dr Johnson), Morrisville, North Carolina; Hôpital du Sacré-Coeur de Montréal (Drs Gautrin and Cartier), Université de Montréal, Montreal, Quebec; Hôpital Laval (Dr Boulet), Université Laval, Sainte-Foy, Québec, Canada; Department of Allergy (Dr Sastre), Fundación Jiménez Díaz and CIBER de Enfermedades Respiratorias CIBERES; Department of Allergy (Dr Quirce), Hospital La Paz-IdiPAZ and CIBER de Enfermedades Respiratorias CIBERES, Madrid, Spain; Department of Medicine and Dalla Lana School of Public Health (Dr Tarlo), University of Toronto, Ontario, Canada; Hospitals Vall D'Hebron (Drs Cruz and Munoz), Barcelona and CIBER de Enfermedades Respiratorias CIBERES, Madrid, Spain; and School of Public Health (Dr Luster), West Virginia University, Morgantown.
Abstract
OBJECTIVE: To investigate whether genetic variants of N-acetyltransferase (NAT) genes are associated with diisocyanate asthma (DA). METHODS: The study population consisted of 354 diisocyanate-exposed workers. Genotyping was performed using a 5'-nuclease polymerase chain reaction assay. RESULTS: The NAT2 rs2410556 and NAT2 rs4271002 variants were significantly associated with DA in the univariate analysis. In the first logistic regression model comparing DA+ and asymptomatic worker groups, the rs2410556 (P = 0.004) and rs4271002 (P < 0.001) single nucleotide polymorphisms and the genotype combination, NAT2 rs4271002*NAT1 rs11777998, showed associations with DA risk (P = 0.014). In the second model comparing DA+ and DA- groups, NAT2 rs4271002 variant and the combined genotype, NAT1 rs8190845*NAT2 rs13277605, were significantly associated with DA risk (P = 0.022, P = 0.036, respectively). CONCLUSIONS: These findings suggest that variations in the NAT2 gene and their interactions contribute to DA susceptibility.
OBJECTIVE: To investigate whether genetic variants of N-acetyltransferase (NAT) genes are associated with diisocyanateasthma (DA). METHODS: The study population consisted of 354 diisocyanate-exposed workers. Genotyping was performed using a 5'-nuclease polymerase chain reaction assay. RESULTS: The NAT2rs2410556 and NAT2rs4271002 variants were significantly associated with DA in the univariate analysis. In the first logistic regression model comparing DA+ and asymptomatic worker groups, the rs2410556 (P = 0.004) and rs4271002 (P < 0.001) single nucleotide polymorphisms and the genotype combination, NAT2rs4271002*NAT1rs11777998, showed associations with DA risk (P = 0.014). In the second model comparing DA+ and DA- groups, NAT2rs4271002 variant and the combined genotype, NAT1rs8190845*NAT2rs13277605, were significantly associated with DA risk (P = 0.022, P = 0.036, respectively). CONCLUSIONS: These findings suggest that variations in the NAT2 gene and their interactions contribute to DA susceptibility.
Authors: Andrew D Johnson; Robert E Handsaker; Sara L Pulit; Marcia M Nizzari; Christopher J O'Donnell; Paul I W de Bakker Journal: Bioinformatics Date: 2008-10-30 Impact factor: 6.937
Authors: E D Bateman; S S Hurd; P J Barnes; J Bousquet; J M Drazen; J M FitzGerald; P Gibson; K Ohta; P O'Byrne; S E Pedersen; E Pizzichini; S D Sullivan; S E Wenzel; H J Zar Journal: Eur Respir J Date: 2008-01 Impact factor: 16.671
Authors: Cassandra C Brooks; Lisa J Martin; Valentina Pilipenko; Hua He; Grace K LeMasters; James E Lockey; David I Bernstein; Patrick H Ryan; Gurjit K Khurana Hershey; Jocelyn M Biagini Myers Journal: J Asthma Date: 2019-12-06 Impact factor: 2.515